BioSpace News Archive

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2021.

Seagen Inc. reported financial results for the third quarter and nine months ended September 30, 2021.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced its submission of a Marketing Authorization Application (“MAA”) for bardoxolone methyl (“bardoxolone”) to the European Medicines Agency (“EMA”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 4th, 2021.

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2021.

Hyperfine, Inc., creator of the first FDA-cleared portable magnetic resonance imaging device, Swoop®, announced the appointment of Scott White as chief commercial officer.

Agilent Technologies Inc. (NYSE: A) will release fourth-quarter fiscal year 2021 financial results after the stock market closes on Monday, November 22.

Vicarious Surgical Inc., a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, announced that management will participate in the Credit Suisse 30th Annual Healthcare Conference.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) to evaluate the efficacy of Gilead’s Trop-2 targeting antibody-drug conjugate Trodelvy® .